“Diabesity” represents a growing global health concern, highlighting the strong biological link between obesity and type 2 diabetes. 1 Managing glycaemia alone may aggravate obesity, particularly with therapies that cause weight gain, highlighting the need for a dual-focused treatment strategy. Effective management of diabesity emphasizes the use of antidiabetic agents that support weight loss alongside glycaemic control. Semaglutide has shown meaningful reductions in body weight, HbA1c, and insulin requirements, with a favorable safety profile.
2 Join us for a high-impact clinical webinar on 20th December 2025 at 8:00 PM IST , where leading experts will explore the rising dual challenge of diabetes and obesity in routine clinical practice. The session will focus on evolving, real-world approaches to diabesity management. Our expert panel will share evidence-backed insights on why…
